Instructions for Mobosetinib/Mobosetinib

1. Generic names: Mobocertinib, Mobocertinib

Product name:Exkivity, Anweili

Other names: Mobotinib, Mobotinib succinate

2. Who can take moboxetinib? Indications?

Mobocertinib/Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, as detected by an FDA-approved test.

3. What are the side effects of Mobosetinib?

The most common side effects of mobosetinib are diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain. The most common grade 3 or 4 laboratory abnormalities are lymphopenia, increased amylase, increased lipase, decreased potassium, decreased hemoglobin, increased creatinine, and decreased magnesium.

4. How should you take moboxetinib?

Before starting mobosetinib, assessQTc and electrolytes, and correct sodium, potassium, calcium, and magnesium abnormalities; based on the presence ofEGFR exon 20 insertion mutations, select patients with locally advanced or metastatic NSCLC to receive mobosertinib treatment. The recommended dose of mobosetinib is160 mg orally once daily until disease progression or unacceptable toxicity. Take at the same time every day, with or without food. Swallow the mobosetinib capsule whole without opening, chewing, or dissolving the capsule contents.

5. How to store Moboxetinib?

Mobosertinib is supplied as 40 mg capsules and stored at 20°C to 25°C (68°F to 77°F); excursions allowed from 15°C to 30°C (59°F to 86°F).

6. How does Moboxetinib work?

Mobosetinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild-type (WT) EGFR. Following oral administration of moboxetinib, two pharmacologically active metabolites (AP32960 and AP32914) with inhibitory characteristics similar to those of moboxetinib were identified in plasma.

In vitro, mobosetinib also inhibited the activity of other EGFR family members (HER2 and HER4) and an additional kinase (BLK) at clinically relevant concentrations (IC50 values<2nM). In cultured cell models, mobosertinib inhibited cell proliferation driven by different EGFR exon 20 insertion mutation variants at concentrations 1.5- to 10-fold lower than WT-EGFR signaling inhibition. In animal tumor implantation models, mobosetinib demonstrated antitumor activity against xenografts containing EGFR exon 20 insertions of NPH or ASV.

7. What will happen if you overdose on moboxetinib?

There are no data regarding overdose with mobosetinib. Symptoms of overdose may be consistent with the adverse effects of mobosertinib and therefore may include significant gastrointestinal symptoms, pain, fatigue, and rash.

8. What are the precautions for taking Moboxetinib?

In the clinical study of moboxetinib, warnings and precautions such as QTc prolongation and torsade de pointes, interstitial lung disease/pneumonitis, cardiotoxicity, diarrhea, embryo-fetal toxicity have emerged.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a91500-a944-4cb8-b4a8-ae278bcf728d